Evidence map›Paper›PMID 28506922›Full record

ReviewNeuroscience and biobehavioral reviews2017

Oxytocin effects in schizophrenia: Reconciling mixed findings and moving forward.

Ellen R Bradley, Joshua D Woolley

Open access · greenAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Neuroscience and biobehavioral reviews, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 45 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
45citing papers in PubMed, 3 pooled it
14.2field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

45 citing papers in PubMed, 3 syntheses or guidelines pooled it, 89 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Trial
  5. Trial
  6. Trial
  7. Trial
  8. Trial
  9. Neural and behavioral effects of oxytocin administration during theory of mind in schizophrenia and controls: a randomized control trial.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2019
    Trial
  10. Oxytocin increases eye gaze in schizophrenia.Schizophrenia research · 2019
    Trial
  11. Trial
  12. Trial
  13. Trial
  14. Trial
  15. Article
  16. Article
  17. Review
  18. Review
  19. Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 1 institution in 1 country.

Ellen R BradleyDepartment of Psychiatry, University of California, San Francisco, 401 Parnassus Avenue, San Francisco, CA 94143, United States. Electronic address: ellen.bradley@ucsf.edu.
Joshua D WoolleyDepartment of Psychiatry, University of California, San Francisco, 401 Parnassus Avenue, San Francisco, CA 94143, United States.
University of California, San Francisco · US

Funding

TRAINING THE NEXT GENERATION OF MENTAL HEALTH RESEARCHERSR25MH060482 · NIMH · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI DANIEL H MATHALON, Susan M. Voglmaier · 2000 to 2026
$5.2M
Mechanisms and Effects of Oxytocin on Social Cognition in SchizophreniaIK2CX000758 · VA · VETERANS AFFAIRS MED CTR SAN FRANCISCO · PI WOOLLEY, JOSH · 2014 to 2018
–
CSRD VA IK2 CX000758NIMH NIH HHS R25 MH060482
6 · The paper itself

Abstract

Schizophrenia is a severe mental illness that causes major functional impairment. Current pharmacologic treatments are inadequate, particularly for addressing negative and cognitive symptoms of the disorder. Oxytocin, a neuropeptide known to moderate social behaviors, has been investigated as a potential therapeutic for schizophrenia in recent years. Results have been decidedly mixed, leading to controversy regarding oxytocin's utility. In this review, we outline several considerations for interpreting the extant literature and propose a focused agenda for future work that builds on the most compelling findings regarding oxytocin effects in schizophrenia to date. Specifically, we examine underlying causes of heterogeneity in randomized clinical trials (RCTs) conducted thus far and highlight the complexity of the human oxytocin system. We then review evidence of oxytocin's effects on specific deficits in schizophrenia, arguing for further study using objective, precise outcome measures in order to determine whether oxytocin has the potential to improve functional impairment in schizophrenia.

Indexed as

HumansOxytocinSchizophreniaOxytocinNegative symptomsOxytocinSchizophreniaSocial cognition

Identifiers

PMID28506922
PMCPMC5682229
OpenAlexW2613328034

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.